News | Structural Heart | May 16, 2016

Older AFib Patients at Greater Risk of Post-Mitral Valve Repair Tricuspid Regurgitation

Study presented at American Association for Thoracic Surgery annual meeting identifies additional risk factors

AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation

May 16, 2016 — Tricuspid regurgitation (TR) occurs when the heart’s tricuspid valve leaks, allowing blood to flow back from the right ventricle to the right atrium. TR can be secondary to disorders of left-sided heart valves (mitral or aortic). At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a long-term study of patients who underwent mitral valve (MV) repair. They found that although newly developed TR after MV repair was rare, the risk could increase in older patients with atrial fibrillation and impaired heart function.

“Patients who develop TR after MV repair for degenerative diseases are older, have chronic atrial fibrillation, more advanced functional class and impaired left ventricular function at the time of the initial surgery. This is yet another compelling reason to correct mitral regurgitation early,” explained Tirone E. David, M.D., Division of Cardiovascular Surgery, Peter Munk Cardiac Centre, Toronto General Hospital and the University of Toronto.

The study included 1,171 patients who had undergone MV repair between 1985 and 2010, with periodic clinical and echocardiographic assessments for around nine years following surgery. Sixty percent of the patients were men and the average age was 58 years. Preoperatively, 44 percent were classified in New York Heart Association (NYHA) functional classes III and IV for heart failure. In addition to MV repair, 17.1 percent of patients also underwent coronary artery bypass, 11.2 percent had surgical ablation to treat atrial fibrillation (the maze procedure), and 4.7 percent had tricuspid annuloplasty to surgically repair the tricuspid valve using an annuloplasty ring.

Forty-five patients (3.3 percent) developed moderate or severe TR, fourteen of whom had undergone previous surgery to repair the tricuspid valve.

“Although the number of patients who developed TR after MV repair was small in our study, the effect of severe TR was devastating, with a high mortality at one year after the diagnosis, which usually occurred during an episode of heart failure,” commented David.

The investigators found that two factors were significantly predictive of developing TR: older age and preoperative atrial fibrillation. In fact, preoperative atrial fibrillation was associated with a three-fold increased risk of TR. Other factors that appear to be associated with postoperative moderate-to-severe TR are insertion of a permanent pacemaker and the grade of TR within the first month of MV surgery.

Enlarged size of the ring-shaped tissue surrounding the leaflets of the valve, known as the annulus, is thought to be a risk factor for the development of TR. European guidelines on the management of heart valve diseases recommend ≥40 mm as the size indication for tricuspid annuloplasty. However, in this study all patients who developed TR often had tricuspid annulus diameters less than 40 mm, as well as less than moderate TR by echocardiography at the time of the MV repair.

About 25 percent of cases of TR are caused by rheumatic disease, endocarditis, carcinoid disease, traumatic injury or pacemakers/defibrillators. More commonly, TR is caused by left heart disease resulting in pulmonary hypertension, chronic lung disease, pulmonary thromboembolism or right ventricular dysfunction. The diet drug Fen-Phen was also linked to TR.

Symptoms of TR may be difficult to detect but may include weakness and fatigue, active pulsing in the neck veins, reduced urinary output, and swelling in the legs, ankles, feet, or abdomen. Mortality may be attributed to the underlying conditions that cause TR rather than TR itself.

For more information: www.aats.org

Related Content

News | Atrial Fibrillation

June 30, 2022 — A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is ...

Home June 30, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

Home May 02, 2022
Home
News | Atrial Fibrillation

April 12, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement ...

Home April 12, 2022
Home
News | Atrial Fibrillation

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
News | Atrial Fibrillation

March 9, 2022 – Point-of-care screening for atrial fibrillation (A-fib) using a new generation of handheld ...

Home March 09, 2022
Home
News | Atrial Fibrillation
February 28, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the ...
Home February 28, 2022
Home
News | Atrial Fibrillation
February 16, 2022 – A new way of treating arrhythmias, including atrial fibrillation (AF) — the most common heart ...
Home February 16, 2022
Home
Subscribe Now